D2L Announces Createspace to Help Simplify Course Creation with Real-Time Collaboration
SAVANNAH, Ga., July 22, 2025 /CNW/ – D2L, a global leader in learning innovation, today announced during its annual Fusion user conference the launch of its all-new Createspace, the next generation of authoring and content management—now available in beta for all Creator+ users.
Createspace allows educators and course authors to create, edit, and collaborate on content with intuitive tools in a dedicated space before publishing it to learners. Createspace is set to be generally available to all D2L Brightspace users later this year.
'Inspired and informed by our work on Creator+, we are proud to introduce Createspace to help transform authoring and content management within D2L Brightspace,' said Christian Pantel, Chief Product Officer at D2L. 'By giving educators a collaborative space to create and manage content more efficiently all in one place, we are helping them save time, reduce complexity, and focus on what matters most: reaching and engaging learners.'
New Capabilities
D2L also launched a suite of additional features to its core D2L Brightspace learning platform. The latest updates are designed to help educators and learners get even more out of their platform and deliver improved upskilling outcomes.
The new D2L Brightspace offerings include:
Enhancements to Assessments, allowing instructors to quickly reopen quiz attempts, deliver feedback in bulk, and use quiz filters to help analyze results and make grading faster.
Expanded group enrollment capacity, increasing the group size limit from 200 to 3,000 learners, and providing educators with more enhanced filters to tailor groups.
Improved visibility for Parents and Guardians by allowing educators to communicate more effectively through the class list, announcements, and templated emails.
Updates to employee learning with a flexible UX design that can empower organizations to deliver structured, repeatable learning at scale–equipped with progress tracking, prerequisites, and integration with HR systems.
Print Quiz helps educators increase quiz value and accessibility for learners.
'With the latest enhancements to D2L Brightspace, we are giving educators even more powerful tools to help unlock the full potential of learners,' said John Baker, President, Founder and CEO of D2L. 'From expanding group capacity to launching Print Quiz and improving assessment workflows, we're making it easier for educators to deliver highly accessible, future-ready education at scale. By helping to empower learning leaders with innovative tools, we are not just breaking barriers—we are helping to build a future where all learners can thrive.'
Announcing D2L Academy
D2L also announced the launch of D2L Academy, a centralized hub for D2L learning resources to help educators and leaders unlock the full potential of D2L Brightspace. D2L Academy provides access to a comprehensive suite of training material, including more than 40 courses, expert-led live sessions, industry-recognized certifications and support for configuring D2L Brightspace, specifically designed to help empower educators, learning leaders and course administrators.
Enhancements to H5P
New enhancements to H5P to refresh the user experience, providing users with a more intuitive way to build and interact with engaging content – including:
Smart Import powered by generative AI expands to support 56 languages.
A visual, drag-and-drop editing experience to better combine text and multimedia content.
Enhanced accessibility with new ARIA roles and improved keyboard navigation.
Newly redesigned native integration into D2L Creator+.
Explore the D2L product roadmap to learn more about upcoming releases, updates, and features.
About D2L D2L is transforming the way the world learns, helping learners achieve more than they dreamed possible. Working closely with customers all over the world, D2L is on a mission to make learning more inspiring, engaging and human. Find out how D2L helps transform lives and delivers outstanding learning outcomes in K-12, higher education and business at www.D2L.com.
The D2L family of companies includes D2L Inc., D2L Corporation, D2L Ltd, D2L Australia Pty Ltd, D2L Europe Ltd, D2L Asia Pte Ltd, D2L India Pvt Ltd, D2L Brasil Soluções de Tecnologia para Educação Ltda and D2L Sistemas de Aprendizaje Innovadores, S. D2 R.L de C.V., and H5P Group AS.
All D2L and H5P marks are owned by the D2L group of companies. Please visit D2L.com/trademarks for a list of D2L marks. All other trademarks are the property of their respective owners.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
5 hours ago
- Malaysian Reserve
Alto Annual Public Meeting 2025
MONTRÉAL, July 24, 2025 /CNW/ – VIA HFR – VIA TGF Inc. (Alto) will hold its Annual Public Meeting (APM) on Thursday, August 28, 2025 at 10:45 a.m. EDT. The APM will be held virtually, and the public is invited to attend the live webcast. The meeting will be hosted by Martin Imbleau, CEO, Alto; J. Robert S. Prichard, Chair of the Board of Directors, Alto; and Marie-José Nadeau, Vice Chair of the Board of Directors, Alto. The APM will offer an opportunity for attendees to hear about Alto's mandate and main accomplishments from the fiscal year that ended on March 31, 2025. Event Details Date: Thursday, August 28, 2025 Speakers: Martin Imbleau, CEO, Alto; J. Robert S. Prichard, Chair, Alto Board of Directors; Marie-José Nadeau, Vice Chair, Alto Board of Directors Time: 10:45 a.m. EDT To register and watch the live webcast, click here. Members of the public and media are invited to submit questions or comments in advance via corporatesecretariat-secretariatcorporatif@ by August 21 at 11:59 p.m. EDT, or participate during the live webcast on August 28 by submitting inquiries through the chat function. Alto's 2024-25 Annual Report will be available under of the 'Alto and You – Transparency and Trust' section of its website after it is tabled before both Houses of Parliament in the fall of 2025. About Alto Alto is a Crown corporation dedicated to building the largest public infrastructure project in Canada's recent history – the country's first ever, fast, reliable and frequent high-speed rail network. With stations in Toronto, Peterborough, Ottawa, Montreal, Laval, Trois-Rivières and Québec City, this project will connect millions of Canadians living along the country's most densely populated corridor. Alto will bring cities and people closer together and create significant socio-economic benefits that will help generations to come. For more information on this transformative project, visit
Malaysian Reserve
8 hours ago
- Malaysian Reserve
Blenrep (belantamab mafodotin) combinations approved in Canada for the treatment of relapsed/refractory multiple myeloma
Superior efficacy shown in two head-to-head phase III trials, including overall survival in DREAMM-7 Blenrep combinations could redefine treatment as early as first relapse where more effective options are needed1,2,3 First and only approved anti-BCMA-ADC for the treatment of multiple myeloma in Canada MISSISSAUGA, ON, July 23, 2025 /CNW/ – GSK announced today that Health Canada has approved Blenrep (belantamab mafodotin for injection) in combination with bortezomib and dexamethasone, or in combination with pomalidomide and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including lenalidomide for the latter combination. Superior efficacy results, when compared to standard of care, from the pivotal DREAMM-7 and DREAMM-8 phase III trials in relapsed or refractory multiple myeloma support the approval of the Blenrep combinations. These include statistically significant and clinically meaningful progression-free survival (PFS) results versus standards of care in both trials and overall survival (OS) in DREAMM-7.2,3,4 The safety and tolerability profiles of the Blenrep combinations were broadly consistent with the known profiles of the individual agents.2,3 'The approval of Blenrep in Canada represents an advancement for patients with multiple myeloma, a challenging condition marked by repeated cycles of remission and relapse,' said Michelle Horn, Country Medical Head, GSK Canada. 'As the only BCMA-targeted antibody-drug conjugate, Blenrep has been shown to extend survival and remission, supported by data from the DREAMM-7 and DREAMM-8 phase III clinical trials. This approval marks a milestone in offering a treatment option that holds the promise to transform the therapeutic approach for patients facing their first or subsequent relapses.' Blenrep is the first and only anti-BCMA (B-cell maturation antigen) antibody-drug conjugate (ADC) for multiple myeloma, providing patients facing their first and subsequent relapses with a differentiated mechanism of action. Blenrep combinations can be administered to a broad range of patient types without complex pre-administration regimens or hospitalization. 'As patients with multiple myeloma receive combination therapies at diagnosis, the availability of diverse treatment options like Blenrep is vital for prolonging remission and enhancing survival outcomes,' said Martine Elias, Chief Executive Officer of Myeloma Canada. 'This milestone represents a transformative step forward in the treatment landscape, empowering our community and reinforcing our commitment to making myeloma matter while driving progress toward a cure.' In the DREAMM-7 and DREAMM-8 clinical trials, Blenrep combinations consistently benefited a broad range of patients, including those with poor prognostic features or outcomes, such as high-risk cytogenetics or those refractory to lenalidomide. Both trials also showed clinically meaningful improvements across all secondary efficacy endpoints, including deeper and more durable responses versus the respective comparators.2,3 The most common adverse reactions, occurring in ≥20% of patients, were reduced visual acuity (BCVA), corneal examination findings, blurred vision, dry eye, photophobia, foreign body sensation in eyes, eye irritation, eye pain, cataract, upper respiratory tract infection, pneumonia, fatigue, thrombocytopenia, diarrhea, and peripheral sensory neuropathy. Eye-related side effects, a known side effect of treatment with Blenrep, were manageable with extended time between infusions and dose reductions, while maintaining efficacy, and led to low (≤9%) treatment discontinuations in both trials.2,3 About multiple myelomaMultiple myeloma is the third most common blood cancer globally and is generally considered treatable but not curable.5,6 There are approximately more than 180,000 new cases of multiple myeloma diagnosed globally each year.7 Multiple myeloma is a significant concern in Canada, where in 2024 alone, 4,000 people were diagnosed with the disease.8 Research into new therapies is needed as multiple myeloma commonly becomes refractory to available treatments.1 About Blenrep Blenrep is an ADC comprising a humanized BCMA monoclonal antibody conjugated to the cytotoxic agent auristatin F via a non-cleavable linker. In Canada, Blenrep (belantamab mafodotin for injection) is indicated for the treatment of adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy. Specifically, Blenrep is indicated: in combination with bortezomib and dexamethasone (BVd), in adult patients who have received at least one prior therapy; and in combination with pomalidomide and dexamethasone (BPd), in adult patients who have received at least one prior line of therapy, including lenalidomide. Please consult the Product Monograph at for complete safety information. The Product Monograph is also available by calling 1-800-387-7374. About DREAMM-7DREAMM-7 is a multicentre, open-label, randomized phase III clinical trial evaluating the efficacy and safety of belantamab mafodotin combined with bortezomib plus dexamethasone (BVd) compared to daratumumab combined with bortezomib plus dexamethasone (DVd) in adult patients with relapsed or refractory multiple myeloma who previously were treated with at least one prior line of multiple myeloma therapy. The trial enrolled 494 participants who were randomized 1:1 to receive either BVd or DVd for eight cycles, after which patients received belantamab mafodotin or daratumumab as a monotherapy. The primary endpoint was PFS as per an independent review committee, with secondary endpoints including OS, duration of response (DOR), and minimal residual disease (MRD) negativity. Other secondary endpoints include overall response rate (ORR), safety, and patient-reported quality-of-life outcomes. The Blenrep combination demonstrated a statistically significant and clinically meaningful improvement in PFS. The median PFS was 36.6 months (95% CI: 28.4-not reached [NR]) with BVd compared to 13.4 months (11.1-17.5) with DVd (hazard ratio for disease progression or death, 0.41; 95% CI, 0.31 to 0.53; P<0.001). For Overall Survival (OS), at the first pre-planned interim analysis, the hazard ratio was 0.57; 95% CI, 0.40, 0.80, indicating a 43% reduction in the risk of death in favour of BVd. More recently, the updated OS results were statistically significant and maintained the reduction in the risk of death in favour of BVd. These results were presented at the American Society of Hematology (ASH) Annual Meeting in December 2024.2,4 These findings were consistently observed in subgroups and supported by secondary endpoints. About DREAMM-8DREAMM-8 is a multicentre, open-label, randomized phase III clinical trial evaluating the efficacy and safety of belantamab mafodotin in combination with pomalidomide plus dexamethasone (BPd) compared to bortezomib and pomalidomide plus dexamethasone (PVd) in adult patients with relapsed/refractory multiple myeloma previously treated with at least one prior line of multiple myeloma therapy, including a lenalidomide-containing regimen. The trial included 302 participants who were randomized 1:1 to receive either BPd or PVd. Patients in DREAMM-8 were more heavily pre-treated in that all had prior exposure to lenalidomide, 81% were refractory to lenalidomide, 25% had prior anti-CD38 exposure and of those most were daratumumab refractory. Belantamab mafodotin was administered at a dose of 2.5mg/kg intravenously for the first cycle and then 1.9mg/kg intravenously every four weeks. The primary endpoint was PFS as per an independent review committee, with key secondary endpoints including OS and MRD negativity rate as assessed by next-generation sequencing. Other secondary endpoints include ORR, DOR, safety, and patient-reported quality-of-life outcomes. In DREAMM-8, the Blenrep combination demonstrated a statistically significant and clinically meaningful improvement in PFS, with a 48% reduction in the risk of disease progression or death compared to PVd (HR: 0.52 [95% CI: 0.37-0.73], p-value<0.001). At the primary analysis, with a median follow-up of 21.8 months, the median PFS was not yet reached (95% CI: 20.6-not yet reached [NR]) with BPd compared to 12.7 months (95% CI: 9.1-18.5) for PVd. Recently, in an updated interim analysis, after a median follow-up of 28.01 months, the mPFS in the BPd arm was 32.6 months compared with 12.5 months in the PVd arm. These results were presented at the European Hematology Association (EHA) Annual Meeting in June 2025.9 The clinical benefit for BPd was observed across all pre-specified subgroups including those with poor prognostic features, such as patients who were refractory to lenalidomide and patients with high-risk cytogenetics. GSK in OncologyOur ambition in oncology is to help increase overall quality of life, maximise survival, and change the course of disease, expanding from our current focus on blood and women's cancers into lung and gastrointestinal cancers, as well as other solid tumours. This includes accelerating priority programmes such as antibody-drug conjugates targeting B7-H3 and B7-H4, and IDRX-42, a highly selective KIT tyrosine kinase inhibitor. About GSK GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at Cautionary statement regarding forward-looking statementsGSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the 'Risk Factors' section in GSK's Annual Report on Form 20-F for 2024, and GSK's Q1 Results for 2025. References _______________________ 1 Nooka AK, Kastritis E, Dimopoulos MA. Treatment options for relapsed and refractory multiple myeloma. Blood. 2015;125(20). doi:10.1182/blood-2014-11-568923. 2 Hungria V, Robak P, Hus M et al. Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2024 Aug 1;391(5):393-407. doi: 10.1056/NEJMoa2405090. Epub 2024 Jun 1. PMID: 38828933. 3 Dimopoulos MA, Beksac M, Pour L, Delimpasi S et al. Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma. N Engl J Med. 2024 Aug 1;391(5):408-421. doi: 10.1056/NEJMoa2403407. Epub 2024 Jun 2. PMID: 38828951. 4 Hungria V, Robak P, H Marek et al. Belantamab Mafodotin, Bortezomib, and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 Trial. Presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition. December 2024 5 Sung H, Ferlay J, Siegel R, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660. 6 Kazandjian D. Multiple myeloma epidemiology and survival: A unique malignancy. Semin Oncol. 2016;43(6):676– 10.1053/ 7 Global Cancer Observatory. International Agency for Research on Cancer. World Health Organization. Multiple Myeloma fact sheet. Available at: Accessed 5 March 2025. 8 Multiple myeloma statistics. Canadian Cancer Society. Available at: Accessed 11 July 2025. 9 UPDATED RESULTS FROM PHASE 3 DREAMM-8 STUDY OF BELANTAMAB MAFODOTIN… – Dimopoulos M – EHA-3268 – Jun 13 2025, Available at:
Malaysian Reserve
10 hours ago
- Malaysian Reserve
MyCreds® Reaches Majority Adoption across Canada's Public Colleges, Institutes, Universities
CALGARY, AB, July 24, 2025 /CNW/ – MyCreds® I MesCertif®, Canada's only sector owned, bilingual, national digital credential network, proudly announces that it has surpassed a major milestone, with 131 publicly funded post-secondary institutions now active on the platform — representing 58% of Canada's publicly funded colleges, universities, and institutes. 'As Canada's nonprofit, sector-governed digital credential network, this achievement is a powerful endorsement of the trust, collaboration, and shared vision we hold with our institutional partners,' said Jodi Tavares, Executive Director of MyCreds I MesCertif. 'Together, we are transforming how learners, employers, and institutions connect through secure, portable, and instantly verifiable digital credentials.' The MyCreds platform provides Canadian learners and credential holders with: Secure, bilingual digital and web wallet to carry transcripts, diplomas, certificates, micro-credentials, and badges Instant, paperless sharing with employers, institutions, government, and licensing bodies Confidence that their data is protected under Canadian and provincial privacy and data residency standards For institutions, MyCreds offers a fully auditable, standards-based system to issue, manage, and revoke credentials, improving efficiency, reducing costs, and supporting learner mobility across Canada and internationally. MyCreds is Canada's official digital credentialing network, owned by the Association of Registrars of the Universities and Colleges of Canada (ARUCC). As a nonprofit-led national trust framework, MyCreds empowers institutions, organizations and issuing bodies to deliver secure, portable digital credentials to millions of learners.
